This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Geron's Stem-Cell Research Hype Soaks Investors

A surefire way to ensure some measure of public enmity is make a public recommendation to short a stem-cell stock. That's what I did on Jan. 26, when I added Geron (GERN - Get Report) as a short to the model portfolio I manage as part of TheStreet.com's Biotech Select investment newsletter.

As I told my subscribers at that time, I'm not against stem-cell medicine, and I certainly hope one day that the field provides medical breakthroughs. I simply don't believe Geron is going to be the company to deliver on the promise of stem cells, based on its ignominious track record of drug development so far.

In fact, the only thing Geron has done exceedingly well in its 13 years as a public company is surf the waves of stem-cell hype and use that momentum to raise lots of money.

Analysis
Discussion
Stock Rating
Biotech Select:
Shorts Show Doubt, Too

Geron reverted to this well-worn tactic again Thursday night, when it quickly sold 7.25 million shares at a price of $6.60, a 14% discount to the stock's Thursday closing price of $7.77. The spot-financing deal grossed Geron about $43 million.

I was the first to report Geron's stock sale Thursday night on RealMoney.com. Geron confirmed the financing in a press release Friday morning but did not disclose the sale price. Geron said the financing will close on Feb. 19.

Geron shares were falling 14% to $6.68 in early Friday trading.

Geron's stock price has moved quickly from $5 to more than $8 in the past few weeks, culminating in the company's Jan. 23 announcement that the Food and Drug Administration had granted the company approval to start a phase I safety study of a human stem-cell therapy in patients with complete spinal cord injury.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
GERN $3.88 0.13%
OSIR $15.46 2.18%
STEM $0.60 1.37%
AAPL $125.01 -0.63%
FB $78.10 0.70%

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs